<?xml version="1.0" encoding="UTF-8"?>
<p>OROV was found in 8.6% of our patients, a smaller prevalence than a previous study in Madre de Dios, were OROV was detected in 24% of samples. However, both prevalences should not be compared since the previous study was conducted analyzing DENV negative samples and again multiple laboratory tests were used (RT-PCR, ELISA IgM, and cellular culture) [
 <xref rid="pone.0187897.ref017" ref-type="bibr">17</xref>]. Moreover, it is difficult to compare our OROV prevalence with previous reports, since OROV is not a notifiable disease in Peru and recent data is unavailable [
 <xref rid="pone.0187897.ref019" ref-type="bibr">19</xref>,
 <xref rid="pone.0187897.ref020" ref-type="bibr">20</xref>]. In our study, 12 patients were positive to OROV and the most common symptoms were headaches (66.7%), joint pain (58.3%) and muscle pain (50%), which is consistent with previous studies in Iquitos and Madre de Dios where fever, headaches, joint and muscle pain were the most predominant symptoms [
 <xref rid="pone.0187897.ref017" ref-type="bibr">17</xref>,
 <xref rid="pone.0187897.ref030" ref-type="bibr">30</xref>].
</p>
